Press release
Epidermolysis Bullosa Clinical Trial Pipeline Robust as 20+ Companies Advance 21+ Gene and Cell Therapies Toward Market Entry, Finds DelveInsight | Abeona Therapeutics, Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, RegeneRx Biopharm
Epidermolysis Bullosa Pipeline Insights
Explore the latest breakthroughs in the Epidermolysis Bullosa treatment landscape. Learn more about the evolving pipeline Epidermolysis Bullosa @ https://www.delveinsight.com/report-store/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Key Takeaways from the Epidermolysis Bullosa Pipeline Report
• In September 2025, the FDA approved label expansion for Krystal Biotech's VYJUVEK (B-VEC, beremagene geperpavec-svdt), extending use to DEB patients from birth with at-home application and flexible dressing removal.
• In May 2025, RELIEF THERAPEUTICS received FDA Rare Pediatric Disease Designation (RPDD) for RLF-TD011 in EB, following prior Orphan Drug Designation.
• IN May 2025, DEBRA Research and Dermaliq Therapeutics formed a strategic collaboration, including investment, to develop topical therapies for EB wound healing, itch relief, and prophylaxis using hyliQ technology.
• In April 2025, the FDA approved ZEVASKYN (prademagene zamikeracel, pz-cel) by Abeona Therapeutics, the first autologous cell-based gene therapy for wounds in RDEB patients.
• The leading Epidermolysis Bullosa companies include Abeona Therapeutics, InMed Pharmaceuticals, BioMendics, RHEACELL, Castle Creek Biosciences, BPGbio, Eloxx Pharmaceuticals, Phoenicis Therapeutics, Aegle Therapeutics, Amryt Pharma, Krystal Biotech, Chiesi, RegeneRx Biopharmaceuticals, BridgeBio Pharma, Holostem Terapie Avanzate, Anterogen Co., Ltd., Fibrocell Science, and others.
• Promising Epidermolysis Bullosa therapies include BPM31510, HOLOGENE-17, AGLE102, RGN-137, PTR-01, INM-755, Dabocemagene autoficel, VYJUVEK, EB-101, FCX-007, SD-101-6.0 cream, ALLO-ASC-SHEET, PTW-002 10 mg/g gel, and others targeting COL7A1 restoration, wound healing, and inflammation modulation across EB subtypes.
Download for Epidermolysis Bullosa recent updates and evolving trends @ https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Epidermolysis Bullosa Emerging Drugs Profile
• EB-101: Abeona Therapeutics
EB-101 (pz-cel) is an autologous cell therapy consisting of genetically corrected keratinocyte sheets engineered from the patient's own skin cells to express functional type VII collagen (COL7), addressing the root cause of dystrophic epidermolysis bullosa (DEB). Applied surgically as a single treatment to chronic wounds, EB-101 promotes durable wound closure, reduces blistering, and alleviates pain by restoring anchoring fibrils at the dermal-epidermal junction. FDA approval was supported by pivotal Phase 3 VIITAL trial results demonstrating statistically significant ≥50% large chronic wound healing and Wong‐Baker FACES pain scale improvement at six months, marking it as a transformative ex vivo gene therapy for recessive DEB.
• AGLE102: Aegle Therapeutics
AGLE102 is a first‐in‐class allogeneic mesenchymal stem cell (MSC) therapy derived from induced pluripotent stem cells (iPSCs), designed for topical application to promote wound healing and reduce inflammation in epidermolysis bullosa wounds. By secreting growth factors, extracellular vesicles, and anti‐inflammatory cytokines, AGLE102 accelerates re‐epithelialization, minimizes scarring, and improves skin integrity without genetic modification. Currently in Phase 2 development, AGLE102 represents a scalable, off‐the‐shelf regenerative approach highlighted by DelveInsight for its potential to address unmet needs in both DEB and junctional EB subtypes.
For more information on the Epidermolysis Bullosa Emerging Drugs Profile, download DelveInsight's comprehensive Epidermolysis Bullosa Pipeline Insight report. @ https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
The Epidermolysis Bullosa Pipeline Report Provides
• Detailed insights about companies developing therapies for Epidermolysis Bullosa, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early‐stage, mid‐stage, and late‐stage of development for Epidermolysis Bullosa treatment.
• Epidermolysis Bullosa companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Epidermolysis Bullosa drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Epidermolysis Bullosa market.
Learn more about Epidermolysis Bullosa drugs opportunities in our groundbreaking research and development projects @ https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Epidermolysis Bullosa Companies
There are 20+ key companies developing therapies for Epidermolysis Bullosa, such as Abeona Therapeutics, Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, RegeneRx Biopharmaceuticals, BridgeBio Pharma, InMed Pharmaceuticals, Fibrocell Science, Holostem Terapie Avanzate, Anterogen Co., Ltd., Castle Creek Biosciences, and others.
DelveInsight's Epidermolysis Bullosa pipeline report notes that Abeona Therapeutics holds one of the most advanced gene‐corrected cell therapy assets with recent FDA approval, while topical and allogeneic stem cell programs from Aegle, Krystal Biotech, and others populate the late‐ and mid‐stage pipeline.
DelveInsight's Epidermolysis Bullosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
• Intravenous
• Subcutaneous
• Oral
• Intramuscular
Epidermolysis Bullosa products have been categorized under various Molecule types such as:
• Monoclonal antibody
• Small molecule
• Peptide
Scope of the Epidermolysis Bullosa Pipeline Report
• Coverage: Global
• Epidermolysis Bullosa companies: Abeona Therapeutics, InMed Pharmaceuticals, BioMendics, RHEACELL, Castle Creek Biosciences, BPGbio, Eloxx Pharmaceuticals, Phoenicis Therapeutics, Aegle Therapeutics, Amryt Pharma and others
• Epidermolysis Bullosa Therapies: BPM31510, HOLOGENE-17, AGLE102, RGN-137, PTR-01, INM-755, Dabocemagene autoficel, VYJUVEK, and others
• Epidermolysis Bullosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Epidermolysis Bullosa Therapeutic Assessment by Clinical Stages: Discovery, Pre‐clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings, read the full details of the Epidermolysis Bullosa Pipeline @ https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
DelveInsight is a leading healthcare‐focused market research and consulting firm that provides clients with high‐quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, DelveInsight offers customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Epidermolysis Bullosa Clinical Trial Pipeline Robust as 20+ Companies Advance 21+ Gene and Cell Therapies Toward Market Entry, Finds DelveInsight | Abeona Therapeutics, Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, RegeneRx Biopharm here
News-ID: 4392763 • Views: …
More Releases from DelveInsight
Traumatic Brain Injury Clinical Trial Pipeline Accelerates as 20+ Pharma Compani …
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2026" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Traumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Spinal Implants Market Size Report 2032: Market Porter's Five Forces Analysis, M …
DelveInsight's Spinal Implants Market Insights Report 2032 provides the current and forecast market analysis, individual leading Spinal Implants Companies market shares, challenges, Spinal Implants Market Drivers, barriers, trends, and key market Spinal Implants companies in the market.
To read more about the latest highlights related to the Spinal Implants Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/spinal-implants-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Spinal…
Genome Editing Market Size Report 2032: Market Porter's Five Forces Analysis, Ma …
DelveInsight's Genome Editing Market Insights Report 2032 provides the current and forecast market analysis, individual leading Genome Editing Companies market shares, challenges, Genome Editing Market Drivers, barriers, trends, and key market Genome Editing companies in the market.
To read more about the latest highlights related to the Genome Editing Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/genome-editing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Genome Editing Market…
Retinopathy of Prematurity Therapeutics Market: Early-Stage Pipeline and FDA Des …
The Retinopathy of Prematurity treatment market is expected to witness significant growth in the coming years, primarily driven by advancements in diagnostic technologies and the development of novel therapeutics by key players such as Novartis, Regeneron, Bayer, FeliQS Corporation, and Infant Bacterial Therapeutics, among others. This growth trajectory is further supported by the rising awareness about Retinopathy of Prematurity management, improvements in neonatal care units, and increasing focus on preventive…
More Releases for Epidermolysis
Epidermolysis Bullosa Market to Reach USD 6.8 Billion by 2034
Epidermolysis bullosa (EB) is a group of rare, genetic skin disorders characterized by fragile skin that blisters and tears easily. Often referred to as "the butterfly skin disease," EB significantly impacts patients' quality of life and requires long-term supportive care. Historically, treatments were limited to wound management and pain control, but recent advancements in gene therapy, cell-based therapies, and biologics are opening new possibilities for disease-modifying interventions.
Download Full PDF Sample…
Epidermolysis Bullosa Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Epidermolysis Bullosa Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 21+ pipeline drugs in Epidermolysis Bullosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Epidermolysis Bullosa Research. Learn more about…
Epidermolysis Bullosa Pipeline, Clinical Trials Assessment, and FDA Approvals 20 …
DelveInsight's, "Epidermolysis Bullosa Pipeline Insight 2023" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Epidermolysis Bullosa pipeline landscape. It covers the Epidermolysis Bullosa pipeline drug profiles, including Epidermolysis Bullosa clinical trials and nonclinical stage products. It also covers the Epidermolysis Bullosa therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Epidermolysis Bullosa Market to Reach US$ 3,856.2 Million by 2033
Market Overview:
The 7 major epidermolysis bullosa markets reached a value of US$ 2,496.5 Million in 2022. Looking forward, IMARC Group expects the 7MM to reach US$ 3,856.2 Million by 2033, exhibiting a growth rate (CAGR) of 4% during 2023-2033.
The report offers a comprehensive analysis of the epidermolysis bullosa market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as…
Singapore Dystrophic Epidermolysis Bullosa Treatment Market to Observe Strong De …
Dystrophic Epidermolysis Bullosa Treatment Market: Introduction
According to the report, the global dystrophic epidermolysis bullosa treatment market was valued over US$ 412 Mn in 2019 and is projected to expand at a CAGR of ~5% from 2020 to 2030. Dystrophic epidermolysis bullosa (DEB) is the second most common form of epidermolysis bullosa. The prevalence of DEB varies from 1 per 49,000 inhabitants in Scotland to 1 per 420,168 in the U.S. According to the U.S. National Library of Medicine,…
Epidermolysis Bullosa Market Insights, Share, Size, Companies, and Forecast 2032
DelveInsight's Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Epidermolysis Bullosa Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Epidermolysis Bullosa Market report covers emerging drugs, current treatment practices, market share of individual therapies, and the current forecasted market size…
